{"id":"cp690-550","safety":{"commonSideEffects":[{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Elevated cholesterol"}]},"_chembl":{"chemblId":"CHEMBL221959","moleculeType":"Small molecule","molecularWeight":"312.38"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CP690,550 (tofacitinib) inhibits JAK1 and JAK3 kinases, which are critical for signal transduction downstream of cytokine receptors involved in immune and inflammatory responses. By blocking JAK signaling, the drug reduces the production of pro-inflammatory cytokines and suppresses T-cell proliferation and activation, thereby dampening pathological immune responses in autoimmune and inflammatory conditions.","oneSentence":"CP690,550 is a JAK inhibitor that selectively blocks Janus kinase signaling to reduce inflammatory cytokine production and immune cell activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:26.131Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Ulcerative colitis"},{"name":"Psoriasis"},{"name":"Polyarticular course juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT03000439","phase":"PHASE3","title":"A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-05-10","conditions":"Arthritis Juvenile Idiopathic","enrollment":100},{"nctId":"NCT01246583","phase":"PHASE2","title":"CP-690-550 Ointment For Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-02-16","conditions":"Psoriasis","enrollment":71},{"nctId":"NCT01743677","phase":"PHASE1","title":"CP-690,550 Thorough QTc Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-10-26","conditions":"Healthy","enrollment":60},{"nctId":"NCT01815424","phase":"PHASE3","title":"A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-12","conditions":"Psoriasis","enrollment":266},{"nctId":"NCT01458574","phase":"PHASE3","title":"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-07-20","conditions":"Ulcerative Colitis","enrollment":593},{"nctId":"NCT01465763","phase":"PHASE3","title":"A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-04","conditions":"Ulcerative Colitis","enrollment":614},{"nctId":"NCT01458951","phase":"PHASE3","title":"A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-06","conditions":"Ulcerative Colitis","enrollment":547},{"nctId":"NCT02001181","phase":"PHASE2","title":"Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-12","conditions":"Dermatitis, Atopic","enrollment":69},{"nctId":"NCT01519089","phase":"PHASE3","title":"A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-03","conditions":"Psoriasis","enrollment":95},{"nctId":"NCT00263328","phase":"PHASE2","title":"Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-12","conditions":"Kidney Transplantation","enrollment":46},{"nctId":"NCT00661661","phase":"PHASE3","title":"Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-04","conditions":"Rheumatoid Arthritis","enrollment":487},{"nctId":"NCT00787202","phase":"PHASE2","title":"A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-12","conditions":"Ulcerative Colitis","enrollment":195},{"nctId":"NCT01262118","phase":"PHASE1","title":"Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-05","conditions":"Rheumatoid Arthritis","enrollment":69},{"nctId":"NCT01740362","phase":"PHASE1","title":"Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-10","conditions":"Renal Impairment","enrollment":24},{"nctId":"NCT00550446","phase":"PHASE2","title":"A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-09","conditions":"Arthritis, Rheumatoid","enrollment":386},{"nctId":"NCT01731327","phase":"PHASE1","title":"A Phase 1 Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of A Modified-Release (MR) Formulation Of Tofacitinib In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-11","conditions":"Healthy","enrollment":20},{"nctId":"NCT01710020","phase":"PHASE1","title":"Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-02","conditions":"End-Stage Renal Disease, Hemodialysis","enrollment":12},{"nctId":"NCT01059864","phase":"PHASE2","title":"Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-02","conditions":"Rheumatoid Arthritis","enrollment":111},{"nctId":"NCT01499004","phase":"PHASE1","title":"A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-11","conditions":"Healthy","enrollment":30},{"nctId":"NCT01405118","phase":"PHASE1","title":"Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-06","conditions":"Rheumatoid Arthritis","enrollment":24},{"nctId":"NCT01202240","phase":"PHASE1","title":"Effect Of Ketoconazole On The Pharmacokinetics Of Tasocitinib (CP-690,550) In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-09","conditions":"Healthy","enrollment":12},{"nctId":"NCT01204112","phase":"PHASE1","title":"Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-09","conditions":"Healthy","enrollment":12},{"nctId":"NCT01185184","phase":"PHASE1","title":"Pharmacokinetics And Safety Study Of Two CP-690,550 Controlled Release Formulation Following Single Dose In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-08","conditions":"Healthy","enrollment":12},{"nctId":"NCT00556257","phase":"PHASE2","title":"Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant Patients","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2007-08","conditions":"Kidney Transplantation","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CP690,550","genericName":"CP690,550","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CP690,550 is a JAK inhibitor that selectively blocks Janus kinase signaling to reduce inflammatory cytokine production and immune cell activation. Used for Rheumatoid arthritis, Ulcerative colitis, Psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}